Serena Coppola

Dr. Serena Coppola

Department of Traslational Medical Science University of Naples Federico II
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SCSerena Coppola
Serena Coppola
CACarmen Avagliano
Carmen Avagliano
ACAntonio Calignano
Antonio Calignano
RCRoberto Berni Canani
Roberto Berni Canani
Worldwide obesity is a public health concern that has reached pandemic levels. Obesity is the major predisposing factor to comorbidities, including type 2 diabetes, cardiovascular diseases, dyslipidemia, and non-alcoholic fatty liver disease. The common forms of obesity are multifactorial and derive from a complex interplay of environmental changes and the individual genetic predisposition. Increasing evidence suggest a pivotal role played by alterations of gut microbiota (GM) that could represent the causative link between environmental factors and onset of obesity. The beneficial effects of GM are mainly mediated by the secretion of various metabolites. Short-chain fatty acids (SCFAs) acetate, propionate and butyrate are small organic metabolites produced by fermentation of dietary fibers and resistant starch with vast beneficial effects in energy metabolism, intestinal homeostasis and immune responses regulation. An aberrant production of SCFAs has emerged in obesity and metabolic diseases. Among SCFAs, butyrate emerged because it might have a potential in alleviating obesity and related comorbidities. Here we reviewed the preclinical and clinical data that contribute to explain the role of butyrate in this context, highlighting its crucial contribute in the diet-GM-host health axis.

3 December 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RNRita Nocerino
Rita Nocerino
Francesca De FilippisFrancesca De Filippis
Francesca De Filippis
GCGaetano Cecere
Gaetano Cecere
AMAntonio Marino
Antonio Marino
MMMaria Micillo
Maria Micillo
RCRoberto Berni Canani
Roberto Berni Canani
Summary: Background: The pathogenesis of infant colic is poorly defined. Gut microbiota seems to be involved, supporting the potential therapeutic role of probiotics.Aims: To assess the rate of infants with a reduction of ≥50% of mean daily crying duration after 28 days of intervention with the probiotic Bifidobacterium animalis subsp. lactis BB‐12® (BB‐12). Secondary outcomes were daily number of crying episodes, sleeping time, number of bowel movements and stool consistency.Methods: Randomized controlled trial (RCT) on otherwise healthy exclusively breastfed infants with infant colic randomly allocated to receive BB‐12 (1 × 109 CFU/day) or placebo for 28 days. Gut microbiota structure and butyrate, beta‐defensin‐2 (HBD‐2), cathelicidin (LL‐37), secretory IgA (sIgA) and faecal calprotectin levels were assessed.Results: Eighty infants were randomised, 40/group. The rate of infants with reduction of ≥50% of mean daily crying duration was higher in infants treated with BB‐12, starting from the end of 2nd week. No infant relapsed when treatment was stopped. The mean number of crying episodes decreased in both groups, but with a higher effect in BB‐12 group (−4.7 ± 3.4 vs −2.3 ± 2.2, P < 0.05). Mean daily stool frequency decreased in both groups but the effect was significantly higher in the BB‐12 group; stool consistency was similar between the two groups. An increase in Bifidobacterium abundance (with significant correlation with crying time reduction), butyrate and HBD‐2, LL‐37, sIgA levels associated with a decrease in faecal calprotectin level were observed in the BB‐12 group.Conclusions: Supplementation with BB‐12 is effective in managing infant colic. The effect could derive from immune and non‐immune mechanisms associated with a modulation of gut microbiota structure and function.

10 September 2024 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
RCRoberto Berni Canani
Roberto Berni Canani
LCLaura Carucci
Laura Carucci
SCSerena Coppola
Serena Coppola
EDEnza D'auria
Enza D'auria
LOLiam O’Mahony
Liam O’Mahony
CVCarina Venter
Carina Venter

1 October 2019 in The Journal of Pediatrics
Verified
Journal Article
Closed access
RNRita Nocerino
Rita Nocerino
MCMargherita Di Costanzo
Margherita Di Costanzo
GBGiorgio Bedogni
Giorgio Bedogni
LCLinda Cosenza
Linda Cosenza
YMYlenia Maddalena
Ylenia Maddalena
RCRoberto Berni Canani
Roberto Berni Canani

12 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
SCSerena Coppola
Serena Coppola
CACarmen Avagliano
Carmen Avagliano
ASAntonia Sacchi
Antonia Sacchi
Sonia LaneriSonia Laneri
Sonia Laneri
ACAntonio Calignano
Antonio Calignano
RCRoberto Berni Canani
Roberto Berni Canani
Human skin is the largest organ and the most external interface between the environment and the body. Vast communities of viruses, bacteria, archaea, fungi, and mites, collectively named the skin microbiome (SM), cover the skin surface and connected structures. Skin-resident microorganisms contribute to the establishment of cutaneous homeostasis and can modulate host inflammatory responses. Imbalances in the SM structure and function (dysbiosis) are associated with several skin conditions. Therefore, novel target for the skincare field could be represented by strategies, which restore or preserve the SM natural/individual balance. Several of the beneficial effects exerted by the SM are aroused by the microbial metabolite butyrate. Since butyrate exerts a pivotal role in preserving skin health, it could be used as a postbiotic strategy for preventing or treating skin diseases. Herein, we describe and share perspectives of the potential clinical applications of therapeutic strategies using the postbiotic butyrate against human skin diseases.

18 September 2024 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
SCSerena Coppola
Serena Coppola
LPLorella Paparo
Lorella Paparo
GBGiorgio Bedogni
Giorgio Bedogni
RNRita Nocerino
Rita Nocerino
DCDavide Costabile
Davide Costabile
RCRoberto Berni Canani
Roberto Berni Canani
Background/Objectives The PREMEDI study was designed to assess the efficacy of nutritional counseling aimed at promoting Mediterranean Diet (MD) during pregnancy on the incidence of overweight or obesity at 24 months in the offspring. Methods PREMEDI was a parallel-arm randomized-controlled trial. 104 women in their first trimester of pregnancy were randomly assigned in a 1:1 ratio to standard obstetrical and gynecological care alone (CT) or with nutritional counseling promoting MD. Women enrolled in the MD arm were provided with 3 sessions of nutritional counseling (one session per trimester). The main outcome was the proportion of overweight or obesity among the offspring at the age of 24 months. Maternal MD-adherence and weight gain during pregnancy were also evaluated. Lastly, the evaluation of epigenetic modulation of metabolic pathways in the offspring was analyzed in cord blood. Results Five women in the MD arm and 2 in the CT arm were lost to follow-up, so a total of 97 completed the study. At 24 months, children of MD mothers were less likely to have overweight or obesity than those of the CT mothers (6% vs. 30%, absolute risk difference = −24%, 95% CI −38% to −9%, p = 0.003, number needed to treat 4, 95% CI 2 to 12, per-protocol analysis). A significantly higher increase of MD-adherence during the trial was observed in the MD arm compared to the CT arm. A similar body weight gain at the end of pregnancy was observed in the two arms. The mean (SD) methylation rate of the leptin gene in cord blood was 30.4 (1.02) % and 16.9 (2.99) % in the MD and CT mothers, respectively (p < 0.0001). Conclusions MD during pregnancy could be an effective strategy for preventing pediatric overweight or obesity at 24 months. This effect involves, at least in part, an epigenetic modification of leptin expression.